Living with relapsing-remitting multiple sclerosis (RRMS) means dealing with unpredictable flare-ups and the constant worry of how the disease will progress over time. Managing these symptoms requires reliable treatments that can keep the condition stable while remaining safe for the patient.
A large review of 66 different studies looked at how cladribine tablets compare to other common medications for RRMS. The results showed that clad1rine significantly reduced the annual relapse rate by 58% compared to a placebo. It also performed better than a placebo in slowing down confirmed disease progression over a six-month period.
While cladribine was found to be an effective and safe option, it did not rank as the top performer among all tested drugs. However, its safety profile was comparable to other oral treatments and interferon beta-1a regimens. This makes it a reliable alternative for patients seeking to manage their symptoms effectively.
